Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Multaq
Dronedarone is an antiarrhythmic medication used to treat certain types of irregular heartbeats (atrial fibrillation and atrial flutter). It belongs to the class of drugs known as multi-ion channel blockers and works by affecting the flow of sodium, potassium, and calcium ions into heart cells, which helps to regulate heart rhythm. Dronedarone is structurally similar to amiodarone but is designed to have fewer side effects.
For maintaining normal heart rhythm in patients with atrial fibrillation or atrial flutter.
Dronedarone is contraindicated in patients with permanent atrial fibrillation or in patients with symptomatic heart failure or severe left ventricular systolic dysfunction (New York Heart Association class II-IV) due to increased risk of death. It is also contraindicated in patients with second- or third-degree atrioventricular block or sick sinus syndrome (unless a functioning pacemaker is in place) due to the risk of severe bradycardia. Use in patients with moderate or severe hepatic impairment is contraindicated due to risk of liver injury.
Outcome:
Increased dronedarone levels, leading to potential toxicity.
Mechanism:
Inhibition of CYP3A4 metabolism.
Outcome:
Increased risk of QT prolongation.
Mechanism:
Additive effects on cardiac repolarization.
Outcome:
Decreased dronedarone levels.
Mechanism:
Induction of CYP3A4 metabolism.
Most likely new formulation: extended-release formulation for improved patient compliance (Year: 2026, 60% confidence)
Based on current usage trends and safety profile, dronedarone is likely to maintain its current FDA approval status with continued monitoring for rare but serious adverse events (55% confidence).
Antiarrhythmic
Benzofuran Derivative